Latest news

• Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

  It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab).

• Baricitinib delay casts a pall over Lilly's results update

  reliance on older products such as Trulicity (dulaglutide) for diabetes and cancer drug Cyramza (ramucirumab).

• Lilly pitches Cyramza at bladder cancer

  The US-based pharma group said its RANGE study of Cyramza (ramucirumab) in patients with locally advanced, unresectable or metastatic urothelial carcinoma (mUC) - the most common form of bladder cancer - could

• Lilly promises solanezumab news in Alzheimer's 'before year-end'

  Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to

• Lilly snags first approval for sarcoma drug Lartruvo

  Lilly still has patent protection for the blockbuster in the US until 2022, and in the meantime needs Lartruvo and other recent launches such as Cyramza (ramucirumab) and Portrazza (necitumumab) to